期刊文献+

改变组织醛固酮及其受体表达对SHR大鼠肾脏纤维化的影响 被引量:2

Effects of Changing Levels of Renal Aldosterone and Its Receptor on Renal Fibrosis in Spontaneously Hypertensive Rats
下载PDF
导出
摘要 【目的】观察改变肾组织醛固酮及其受体水平对自发性高血压大鼠肾脏纤维化的影响。【方法】8周龄的雄性自发性高血压大鼠(SHR)24只及同源正常京都大鼠(WKY)8只,SHR分为贝那普利干预组[30mg/(kg·d)]、大剂量安体舒通干预组[100mg/(kg·d)]和高血压模型对照组,同时设同源的正常对照组,干预时间为8周,检测收缩压、尿蛋白、血白蛋白、尿素氮、肌酐、肾组织醛固酮受体、TGF-β1的mRNA和蛋白表达。【结果】贝那普利能下调组织醛固酮[(15.8±2.6)vs(22.2±0.6)pg/mg]及其受体水平[(15±4)vs(13±5)PU]并减轻肾脏纤维化[(17.0±1.8)vs(20.0±2.3)PU],均为P<0.05;大剂量安体舒通能上调组织醛固酮[(24.3±4.6)vs(22.2±0.6)pg/mg]及其受体水平[(16±6)vs(13±5)PU]并加重肾脏纤维化[(22.6±3.0)vs(20.0±2.3)PU],均为P<0.05。【结论】肾组织醛固酮及其受体水平的改变可能影响高血压肾脏纤维化的过程。 [Objective ] To investigate the effects of different levels of renal aldosterone and its receptors in renal fibrosis in spontaneously hypertensive rats (SHR). [Methods] Twenty-four 8-week-aged male SHRs were divided into three groups: spironolactone group [ 100 mg/(kg·d)], benapril group [30 mg/(kg·d)], hypertension model group. The authors also observed the normal group (eight 8-week-aged male Wistar-Kyoto rats). After eight weeks interference, the authors checked systolic blood pressure, proteiuria, albumin, blood urea nitrogen, and creatinine, the expression of mineralocorticoid receptor and transforming growth factor beta 1 (TGF-β1) in renal tissue. [Results] Benapril down-regulated the levels of renal aldosterone [(15.8+2.6) vs (22.2+0.6) pg/mg] and its receptors [(15±4) vs (13±5) PU], alleviate renal fibrosis [(17.0±1.8) vs (20.0±2.3) PU], all were P〈 0.05, while spironolactone up-regulated the levels of renal aldosterone [(24.3±4.6) vs (22.2±0.6) pg/mg] and its receptor [(16±6) vs (13±5) PU] and aggravated renal fibrosis [(22.6±3.0) vs (20.0±2.3)PU], all were P〈 0.05.[Conclusion]The change of aldosterone and its receptors in kidney can affect the process of renal fibrosis in SHR.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2007年第4期402-407,共6页 Journal of Sun Yat-Sen University:Medical Sciences
基金 广东省自然科学基金项目(05001702)
关键词 醛固酮 醛固酮受体 调节 高血压 肾脏纤维化 aldosterone mineralocorticoid receptor regulation hypertension renal fibrosis
  • 相关文献

参考文献11

  • 1YOSHIDA M,MA J,TOMITA T,et al.Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure[J].Congest Heart Fail,2005,11(1):12-16.
  • 2BEGGAH A T,ESCOUBET B,PUTTINI S,et al.Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes[J].Proc Natl Acad Sci,2002,99(10):7160-7165.
  • 3TAAL MW,ZANDI-NEJAD K,WEENING B,et al.Proinflammatory gene expression and macrophage recruitment in the rat remant kidney[J].Kidney Int,2000,58(4):1664-1676.
  • 4MORIYAMA T,KAWADA N,NAGATOYA K,et al.Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction[J].Kidney Int,2001,59 (6):2095-2103.
  • 5申洪.免疫组织化学染色定量方法研究(Ⅲ)[J].中国组织化学与细胞化学杂志,1995,4(1):89-92. 被引量:398
  • 6高修仁,彭龙云,曾群英,黄顺伟,马虹,罗斌,谢耀群,段大跃.充血性心衰ACEI治疗中醛固酮逃逸现象与心率变异的研究[J].中山大学学报(医学科学版),2003,24(3):277-280. 被引量:4
  • 7DELANO F A,SCHMID-SCHONBEIN G W.Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat[J].Microcirculation,2004,11(1):69-78.
  • 8DE RESENDE M M,KAUSER K,MILL J G.Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats[J].Life Sci,2006,78(26):3066-3073.
  • 9MASSAAD C,LOMBES M,AGGERBECK M,et al.Cell-specific,promoter-dependent mineralocorticoid agonist activity of spironolactone[J].Mol Pharmacol,1997,51(2):285-292.
  • 10RAHMOUNI K,SIBUG R M,DE KLOET,et al.Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA -salt hypertension[J].Eur J Pharmacol,2002,436(3):207-216.

二级参考文献29

  • 1申洪,陆药丹.免疫组织化学染色的定量方法研究[J].生物医学工程学杂志,1993,10(4):281-284. 被引量:126
  • 2梅长林,张黎明,陈蕾.大鼠系膜细胞系的建立及鉴定[J].肾脏病与透析肾移植杂志,1996,5(6):90-92. 被引量:18
  • 3Lombes M,Alfaidy N,Engene E,et al. Prerequisite for cardiac aldosterone action:Mineralocorticoid receptor and 11β-hydroxysteroid delydrogenase in the human heart. Circulation,1995,92:175-182.
  • 4Lijnen P,Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol, 2000,32:865-879.
  • 5Xiao F,Puddefoot JR,Vinson GP.Aldosterone mediates angiotensinII-stimulated rat vascular smooth muscule cell proliferation. J Endocrinol,2000,165:533-536.
  • 6Slight SH,Joseph J,Fanjam VK,et al.Extra-adrenal mineralocorticoids and cardiovascular tissule. J Mol Cell Cardiol,1999,31:1175-1184.
  • 7Mellon SH,Deschepper CF.Neurosteroid biosynthesis genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res,1993,629:283-292.
  • 8Greene EL,Kren S,Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest,1996,98:1063-1068.
  • 9Todo-Turla KM,Schnermann J,Fejes-Toth G,et al.Distribution of mineralocorticoid and glucocorticord receptor mRNA along the nephron. Am J Physiol, 1993,264:F781-791.
  • 10Zhou MY,Elise PG,Diana L, et al.Cloning,Expression,and tissue distribution of the rat nicotinamide adenine dinucleotide dependent 11β-Hydroxysteroid Dehydrogenase. Endocrinology 1995,136:3729-3734.

共引文献426

同被引文献20

  • 1杨念生,武庆庆,杜勇,张锐,李幼姬,叶任高,余学清.影响IgA肾病预后的危险因素分析[J].中华内科杂志,2005,44(8):597-600. 被引量:67
  • 2陈铖,丁国华,梁伟,贾俊亚,杨红霞.醛固酮抑制Akt活性诱导大鼠足细胞凋亡[J].中华肾脏病杂志,2006,22(8):467-471. 被引量:10
  • 3袁军,贾汝汉,包艳,丁国华.活性氧和转化生长因子β1在醛固酮上调纤溶酶原激活物抑制剂1中的作用[J].中华肾脏病杂志,2006,22(12):758-762. 被引量:8
  • 4McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature [J]. Nephrol Dial Transplant, 2011, 26(2) : 414-430.
  • 5Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA nephropathies [J]. Pediatr Nephrol, 2001, 16(2) : 156-167.
  • 6Ohashi N, Urushihara M, Kobori H. Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy [J]. Minerva Urol Nefrol, 2009, 61(1): 55-66.
  • 7Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD[J]. Am J Kidney Dis, 2006, 45(5) : 752-760.
  • 8Santangelo F, Witko-Sarsat V, Drueke T, et al. Restoring glutathione as a therapeutic strategy in chronic kidney disease [J]. Nephrol Dial Transplant, 2004, 19 (8) : 1951-1955.
  • 9Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia [J]. Kidney Int, 1996, 49(5): 1304-1313.
  • 10Katafuchi R, Kiyoshi Y, Oh Y, et al. Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation [ J ]. Clin Nephrol, 1998, 49 ( 1 ) : 1-8.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部